| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 75511 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
76 |
h |
2024-12-19 |
| 75512 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
80 |
WYQ |
2024-12-19 |
| 75513 |
Arm-DOTA-B72.3 |
74 |
h |
2024-12-19 |
| 75514 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
89 |
zyl |
2024-12-19 |
| 75515 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
123 |
h |
2024-12-19 |
| 75516 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
84 |
kx |
2024-12-19 |
| 75517 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
86 |
h |
2024-12-19 |
| 75518 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
108 |
WYQ |
2024-12-19 |
| 75519 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
119 |
zyl |
2024-12-19 |
| 75520 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
109 |
kx |
2024-12-19 |
| 75521 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
111 |
wyh |
2024-12-19 |
| 75522 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
74 |
h |
2024-12-19 |
| 75523 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
91 |
h |
2024-12-19 |
| 75524 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
113 |
wyh |
2024-12-19 |
| 75525 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
89 |
h |
2024-12-19 |
| 75526 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
119 |
WYQ |
2024-12-19 |
| 75527 |
1626359-62-3，SPDB-DM4， ADC试剂 |
79 |
kx |
2024-12-19 |
| 75528 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
83 |
WYQ |
2024-12-19 |
| 75529 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
107 |
wyh |
2024-12-19 |
| 75530 |
DOTA-(D)Phe(1)-Tyr(3) |
77 |
h |
2024-12-19 |
| 75531 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
118 |
zyl |
2024-12-19 |
| 75532 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
120 |
WYQ |
2024-12-19 |
| 75533 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
76 |
h |
2024-12-19 |
| 75534 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
90 |
WYQ |
2024-12-19 |
| 75535 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
110 |
wyh |
2024-12-19 |
| 75536 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
129 |
WYQ |
2024-12-19 |
| 75537 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
165 |
kx |
2024-12-19 |
| 75538 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
81 |
h |
2024-12-19 |
| 75539 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
93 |
wyh |
2024-12-19 |
| 75540 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
112 |
zyl |
2024-12-19 |
| 75541 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
133 |
WYQ |
2024-12-19 |
| 75542 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
99 |
kx |
2024-12-19 |
| 75543 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
103 |
h |
2024-12-19 |
| 75544 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
89 |
WYQ |
2024-12-19 |
| 75545 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
70 |
wyh |
2024-12-19 |
| 75546 |
cas:330970-70-2 Alloc-Val-Ala-OH |
86 |
zyl |
2024-12-19 |
| 75547 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
70 |
h |
2024-12-19 |
| 75548 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
72 |
WYQ |
2024-12-19 |
| 75549 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
115 |
kx |
2024-12-19 |
| 75550 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
80 |
WYQ |
2024-12-19 |
| 75551 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
168 |
kx |
2024-12-19 |
| 75552 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
113 |
WYQ |
2024-12-19 |
| 75553 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
111 |
h |
2024-12-19 |
| 75554 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
100 |
zyl |
2024-12-19 |
| 75555 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
82 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询